Ownership
Private
Stage
Phase 1
Modalities
Autologous cell therapyGene therapyTumor-infiltrating lymphocyte therapy (TIL)

Obsidian Therapeutics General Information

Developing OBX-115, an engineered TIL therapy with regulatable membrane-bound IL15. Currently in Phase 1/2 trials for melanoma and NSCLC. Received RMAT designation for advanced melanoma.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

OBX-115
Phase 1/2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Obsidian Therapeutics's pipeline data

Book a demo

Key Partnerships

Bristol Myers Squibb, Vertex Pharmaceuticals

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Obsidian Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Obsidian Therapeutics's complete valuation and funding history, request access »

Obsidian Therapeutics Investors

Wellington Management
Investor Type: Venture Capital
Holding: Minority
Novo Holdings US
Investor Type: Venture Capital
Holding: Minority
and other blue chip investors (specific names not all listed)
Investor Type: Venture Capital
Holding: Minority